ArticleOpen life sciences2024
Unleashing of cytotoxic effects of thymoquinone-bovine serum albumin nanoparticles on A549 lung cancer cells.
Article in Open life sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Novel Thymoquinone Derivative TQFL28 Inhibits Triple-Negative Breast Cancer (TNBC) Invasiveness In Vitro and In Vivo.Current issues in molecular biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research examines the cytotoxic consequences of thymoquinone-loaded bovine serum albumin nanoparticles (TQ-BSA NPs) on the A549 lung cancer cell line. UV-visible (UV-Vis) spectroscopy, Fourier transform infrared spectrophotometer (FT-IR), scanning electron microscopy (SEM), and dynamic light scattering (DLS) were employed to verify the biogenic TQ-BSA NPs' size, shape, and distribution. UV-Vis spectrophotometry indicated peaks at 200-300 nm, 500-600 nm, and a prominent peak at 700-800 nm, confirming the presence of TQ-BSA NPs. The polydispersity index, as confirmed by DLS, indicated a solvent distribution in water, accompanied by a zeta potential value of 126.2 ± 46.8 mV. The average size of TQ-BSA NPs was confirmed to be 187 ± 8 nm by SEM. TQ-BSA NPs reduce colony formation in the A549 lung cancer cell line in a dose-dependent manner relative to the control group. Protein expression analysis indicated that TQ-BSA NPs promoted programmed cell death by increasing pro-apoptotic levels and decreasing anti-apoptotic levels. TQ-BSA NPs demonstrated inhibition of cancer cell proliferation and promotion of apoptosis and exhibited significant efficacy against cancer cells at low concentrations. As a result, they have the makings of a promising chemotherapeutic agent for low-dose, long-term administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.